Henri Termeer Dies Aged 71
Biotech mourns the loss of one of its giants.
You may also be interested in...
Serial entrepreneur Michael Gilman has taken the helm of another start-up; after selling Padlock to Bristol-Myers and Stromedix to Biogen, his new company Arrakis has raised a $38m Series A round with big biopharma backing.
Moderna is in no rush to conduct an IPO, but the secretive biopharma unicorn gave potential investors in a future offering a glimpse of its 12 programs in or nearing the clinic at J.P. Morgan’s annual conference.
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.